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The BCL2 (B cell lymphoma/leukemia-2) proto-onco- 
gene  encodes  a  26-kDa protein that has  been  localized 
to the inner mitochondrial membrane and  that has  been  
shown to enhance  the survival of some types of hemato-  
poietic cells. Here we show that NIH3T3 fibroblasts 
stably transfected with a  BCL2 expression plasmid ex- 
hibit reduced dependence  on  competence- inducing 
growth factors (platelet-derived growth factor, PDGF; 
epidermal growth factor, EGF) for initiation of DNA 
synthesis. The  importance of BCL2 for growth factor- 
induced proliferation of these cells was further con- 
firmed by the useage  of BCL2 ant isense ol igodeoxynu- 
cleotides. The  mechanisms by which overexpression of 
p26  BCL2 contributes to fibroblast proliferation are un-  
known, but do  not involve alterations in: (a) the produc- 
tion of inositol t r iphosphates (IP,), (b) PDGF-induced 
transient elevations in cytosolic Ca2+ ions, or (c) the ac- 
tivity of protein k inase C enzymes in these transfected 
cells. The  results imply that changes  in mitochondrial 
functions play an  important role in the early stages of 
the cell cycle that render 3T3  cells competent  to re- 
spond  to the serum progression factors that stimulate 
entry into S-phase. cc) 1991 Academic Press, Inc. 
INTRODUCTION 
The B cell lymphoma/leukemia-2 (BCLS) oncogene 
encodes a 26-kDa integral membrane protein that has 
been implicated in the earliest stages of lymphoma de- 
velopment in humans [ 11. Though comparisons of p26 
BCL2 with other protein sequences available in data- 
bases have provided few clues about the possible activi- 
ties of this oncopeptide, recently the BCL2-encoded 
protein has been localized by confocal immunofluores- 
cence microscopy and subcellular fractionation to the 
‘To whom correspondence and reprint requests should be ad- 
dressed. 
inner mitochondrial membrane [2]. Presumably, there- 
fore, BCL2 regulates some aspect of mitochondrial 
function. Gene transfer studies have shown that over- 
expression of p26 BCL2 can markedly enhance the sur- 
vival of some types of hematopoietic cells without con- 
comitantly stimulating cellular growth [2-51, a finding 
consistent with the mitochondrial location of the BCL2 
protein. In fact, because of its cell survival enhancing 
activity, no strong evidence has yet been presented to 
indicate that BCL2 can regulate cell cycle entry or pro- 
gression. 
Investigations of the regulation of BCL2 proto-onco- 
gene expression in normal cells are limited to human 
lymphocytes. In quiescent lymphocytes, BCL2 gene 
transcription is induced within an hour of stimulation 
with mitogenic agents, peaks at 6-8 h, and then declines 
later as cellular proliferation begins to wane in the cul- 
tures [6]. These findings have suggested a role for BCL2 
in the control of normal cellular proliferation. We  there- 
fore explored the actions of BCL2 using the 3T3 fibro- 
blast model for normal cellular growth regulation. Un- 
like the hematopoietic cell lines used for previous gene 
transfer studies of BCLS, quiescent 3T3 fibroblasts can 
survive for several days in defined media without 
growth factors. The murine fibroblasts thus permitted 
us to examine the effects of BCL2 on cellular prolifera- 
tion, in the absence of confounding cell survival issues. 
We  also followed up on a previous report showing that 
overexpression of p26 BCL2 caused elevated phosphati- 
dylinositol (PI) turnover and increased synthesis of 
phosphatidic acid (PA) in NIH3T3 fibroblasts [7]. Be- 
cause PI turnover and PA production have been linked 
to regulation of inositol [l, 4, 51 triphosphate produc- 
tion (IP,) (a second messenger that controls cytosolic 
calcium ion concentrations) and protein kinase-C 
(PKC) activity [8, 91, we therefore measured relative 
rates of IP, synthesis and platelet-derived growth factor 
(PDGF)-induced transient elevations in cytosolic Ca2+ 
ions and examined PKC enzyme levels and activity in 
BCL2-expressing 3T3 cells. 
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METHODS 
Cells. The NIH3T3 cell lines R596.2 and R658.2 are stably trans- 
fected with the pSV%BCLZa expression plasmid and have been de- 
scribed previously [lo]. The RAS-transformed NIH3T3 cells R596.7 
(Ref. [lo]) and C74-81 (gift of A. Cuadrato) were transfected with 
pEJ6.6 plasmid, containing the human HA-C-RAS oncogene. The 
3T3 cell lines R596.1 and R596.3 were transfected with the pSVP- 
GPT and pSV2-BCL2-AS (antisense) plasmids as described 
previously [lo]. All cell lines were carefully maintained between 20 
and 90% confluence in Dulbecco’s modified Eagles’ medium 
(DMEM) supplemented with 10% (v:v) calf serum (Hyclone). To 
avoid accumulation of secondary genetic events, cells were reestab- 
lished in culture from frozen stocks every 6-8 weeks. 
RNA blot analysis. Total cellular RNA was isolated by a guani- 
dine-isothiocyanate/phenol procedure [II], and the polyadenylated 
fraction was purified by oligodeoxythymidine-cellulose chromatogra- 
phy [12]. Approximately 5-pg aliquotes of mRNA were size-fraction- 
ated in 0.8% agarose/6% formaldehyde gels and transferred to nylon 
membranes. Blots were prehybridized, hybridized, and washed ex- 
actly as described [13], using either a ‘*P-cDNA for human bcl-2, pB4 
[14], or a murine bcl-2 probe, pMBCL5.4 [15]. Blots were exposed to 
Kodak XAR film with intensifying screens at -70°C for l-10 days. 
Eluting 32P-bcI-2 probes from membranes and rehybridizing with a 
“P probe for mouse beta-2-microglobulin verified nearly equivalent 
amounts of mRNA for all samples on blots (not shown). 
Measurements of DNA synthesis. Relative levels of growth factor- 
induced DNA synthesis were determined in NIH3T3 cells by measur- 
ing [3H]thymidine incorporation, as described [16]. Briefly, after 
reaching confluence in 35.mm dishes, monolayers of 3T3 cells were 
washed twice with 2 ml DMEM and cultured for 24 h in DMEM 
without serum. The media were then replaced with 1 ml of DMEM 
containing O-20 rig/ml recombinant PDGF (Bakchem DRG030A), 
O-10 rig/ml epidermal growth factor (EGF) (Boerhinger-Mannheim), 
200 rig/ml recombinant insulin-like growth factor-I (IGF-I) (Gen- 
zyme 1211.OO), or various combinations of these growth factors. After 
6 h, 1 &i/ml [3H]thymidine (sp act - 6 Ci/mmol) was added to each 
dish and 12 h later cells were recovered by trypsinization and washed, 
and their DNA was precipitated with 10% trichloroacetic acid onto 
glass filters (Schleicher & Schuell32). Filters from duplicate cultures 
were then analyzed by scintillation counting and the data were aver- 
aged (i standard error). 
Preparation and use of BCLB-antisense oligodeoxynucleotides. The 
sequences of the BCLP antisense oligodeoxynucleotides (ODNs) and 
control ODNs used for these studies were the same as described 
previously and were complementary to either the sense (TI-AS) or 
antisense (TI-S) strands of the human BCL2 gene in the vicinity of 
the translation initiate site [17]. ODNs were synthesized using an 
Applied Biosystems 380B DNA synthesizer and purified using HPLC 
reverse-phase chromatography (PRP-1 column) and C18-Sep-Pak 
chromatography (Waters Associates, Millipore, Inc.) as described 
previously [17]. Oligodeoxynucleotides eluted in 30% acetonitrile 
were evaporated to dryness, resuspended at l-2 mM in sterile Hanks’ 
buffered salt solution (GIBCO), and the pH was adjusted to 7.4 prior 
to storage at -80°C in small aliquots. ODNs were added to cultures of 
3T3 cells containing 5% (v:v) fetal calf serum (FSC) that had been 
heated at 68°C for 1 h to reduce levels of active nucleases. 
Measurement of [3H]inositol phosphates. Confluent cultures were 
labeled for 48 h in inositol-free DMEM with 1 &i/ml [3H]myo- 
inositol. The cells were then washed and placed in media containing 
20 mM LiCl, and incubated for 10 min at 37°C. Bradykinin (1 FM) 
and PDGF (20 rig/ml) were added for 5 min and the reactions were 
terminated by addition of 1.5 ml chloroform:methanol:hydrochloric 
acid (100:200:2). The cells were scraped from the dishes and the ex- 
tracts were separated into two phases by addition of 0.5 ml each, 
water and chloroform. The upper aqueous phases were removed, neu- 
tralized with 1 M NaOH, and diluted with water to 3 ml. The samples 
were applied to l-ml Dowex columns (AG l-X8, formate form, 200- 
400 mesh). [3H]Inositol phosphates were eluted as previously de- 
scribed [ 181. 
Ca2+ measurements. Subconfluent monolayers of 3T3 fibroblasts 
grown on uncoated glass coverslips were deprived of serum overnight, 
then loaded with fura- by incubating with the acetoxy-methylester 
of fura- (fura2/AM) (15 PM) for 2 h. Fluorescence of single fura-2- 
loaded cells was measured using a 100X Nikon Fluor objective and a 
Nikon Diaphot epiAuorescent microscope illuminated with alternat- 
ing (100 Hz) 340 and 380 nm excitation lights, and fluorescent emis- 
sions were collected at 520 nm (50 nm half bandwidth) by a photo- 
multiplier tube. Output from the fluorometer was digitized, and the 
380/340 nm ratio was determined and analyzed by using an AT-based 
analysis system (Indec, Sunnyvale, CA). Calibration of the fluores- 
cent signal and calculation of cytosolic-free Ca*+ was performed by 
the method of Grynkiewicz et al. [19]. Cells were perfused with 40 
rig/ml of PDGF using micropipets. 
Immunoblot detection of PKC. Rabbit antisera 201 with panreac- 
tivity for PKCs u, p, and d was prepared using a synthetic peptide as 
an immunogen that corresponded to the 12 amino acids covering the 
pseudosubstrate region of rat PKCB [20]. The specificity of this anti- 
serum has been demonstrated by peptide competition studies and 
analysis of cells that contained various PKC isoenzymes. Detergent 
lysates were normalized for protein content, and 100 pg/lane size 
fractionated by 7.5% SDS-PAGE prior to immunoblot analysis as 
described previously [20]. 
Measurement ofphosphorylation of p68 MARCKS. Quiescent 3T3 
cells in loo-mm dishes were incubated in 2.5 ml PO,-free media for 
2-3 h prior to labeling with 1.0 mCi 32P0, for 2-3 h. Some cultures of 
cells were then stimulated with 100 rig/ml tetradecanoylphorbol ace- 
tate (TPA) (Calbiochem) for 5 min prior to lysis of cells in a modified 
RIPA buffer (containing 20 mM NaF and 1 mM Na-ortho-vanadate) 
and immunoprecipitation of p68-MARCK (myristylated alanine-rich 
C-kinase substrate), using methods essentially as we have described 
previously [20]. For these experiments, detergent lysates were ad- 
justed to 1 mg/ml (total protein) and 5 ~1 of anti-MARCKS antiserum 
was added to 500 ~1 of cellular lysates for 4 h at 4°C prior to addition 
of protein A Sepharose. The rabbit antiserum R435 used for these 
studies (gift of A. Nairn and P. Greengard) was prepared against the 
MARCKS protein purified from rat brain 1211. This antiserum cross- 
reacts with the ~68 MARCKS protein of murine cells [22]. 
RESULTS AND DISCUSSION 
Influence of BCL2 ongrowth factor requirements. We 
used two independently derived pSV2-BCL2-trans- 
fected 3T3 cell lines for these studies (R596.2, R658.2) 
and made direct comparisons with negative control 
(pSV2-gpt-transfected cells, R596.1) and positive con- 
trol (pEJ6.6-transfected cells, R596.7 and C74.81) cell 
lines. Polyclonal cell lines were employed to avoid 
clonal bias. As reported previously [lo], BCLB-express- 
ing NIH3T3 fibroblasts retained normal morphology 
for months in continuous culture. These cells grew to 
similar densities as untransfected NIH3T3 cells and the 
negative control cell line R596.1. When deprived of 
serum, the BCL2-expression (R596.2; R658-2) and nega- 
tive control-transfected (R596.1) cell lines also achieved 
equivalent levels of quiescence as determined by propi- 
dium iodide-based cell cycle analysis (l-2% of cells were 
in S-, G2-, or M-phases at 2 days after serum with- 
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FIG. 1. BCL2 reduces growth factor requirements for optimal DNA synthesis by NIH 3T3 cells. 3T3 cells at confluence in serum-free 
medium were stimulated for 6 h with 20 rig/ml IGF-I and either O-20 rig/ml of PDGF (A) or 0610 rig/ml EGF (B). SH-TdR (1 &i/ml) was then 
added and 12 h later cellular DNA was precipitated with 10% trichloroacetic acid and collected on filters that were subjected to scintillation 
counting. Data are expressed as a percentage relative to maximum and represent the mean f standard errors of three independent experi- 
ments using the control cell line R596.1 (GPT [O]), and the R596.2, R658.2 (BCLB [O]), and the R596.7 and C74-81 (RAS [0]) cell lines. 
drawal). Comparable numbers of viable cells were also 
recovered from serum-deprived cultures of R596.1, 
R596.2, and R658.2 cells, indicating that BCL2 expres- 
sion did not differentially influence the survival of 
NIH3T3 under these conditions (not shown). 
In initial experiments, serum-deprived quiescent 3T3 
cells were supplied with optimal amounts of a progres- 
sion factor (200 rig/ml IGF-I), and various concentra- 
tions of a competence factor (O-20 rig/ml PDGF) [23]. 
Relative levels of DNA synthesis ( [3H]thymidine incor- 
poration) were then measured 18 h after growth factor 
additions. As shown in Fig. lA, the BCL2-expressing 
3T3 cell lines exhibited reduced dependence on PDGF 
for induction of maximal DNA synthesis when com- 
pared to negative control (R596.1) transfected cells. 
The maximal PDGF-induced DNA synthesis in these 
cultures corresponded to 65-85% of cells entering the 
cell cycle (based on propidium iodide analysis (not 
shown)) for both BCL2-expressing and negative control 
of 3T3 cells. As expected, the RAS-transformed cell 
lines (used as a positive control) also displayed reduced 
dependence on PDGF for induction of maximal DNA 
synthesis (Fig. 1). When other competence factors such 
as EGF (Fig. 1B) and bFGF (not shown) were substi- 
tuted for PDGF, similar results were obtained. 
Though 3T3 cells expressing BCL2 were capable of 
achieving maximal DNA synthesis with reduced 
amounts of competence factors such as PDGF, EGF, 
and bFGF, the inclusion in cultures of optimal concen- 
trations of either IGF-I or insulin was absolutely re- 
quired for maximal proliferation. Addition of 20 rig/ml 
PDGF alone to cultures of R596.2 and R658.2 cells re- 
sulted in less than a twofold increase in [3H]thymidine 
incorporation, whereas the combination of 20 rig/ml 
PDGF and 20 rig/ml IGF-I resulted in a greater than 
sevenfold increase in DNA synthesis (Fig. 1A and not 
shown). Similar results were obtained when insulin or 
PDGF-poor plasma was substituted for IGF-I (unpub- 
lished). Thus, overexpression of p26-BCL2 allowed 
these NIH3T3 cells to synthesize DNA maximally in the 
presence of reduced concentrations of competence-in- 
ducing growth factors (PDGF, EGF, bFGF), but not in 
the absence of progression factors (IGF-I, insulin). 
Given p26-BCL2’s intramitochondrial location [2], 
these results imply that alterations in mitochondrial 
function may play an important role in the early stages 
of the cell cycle that render cells competent to respond 
to serum progression factors such as IGF-I and insulin. 
In this regard, it is of interest that several hormones and 
growth factors have been shown to influence mitochon- 
drial metabolism [ 241. 
To confirm the importance of BCL2 overexpression 
for the observed enhanced proliferative activity of 
pSV2-BCL2-transfected 3T3 cells, we employed BCL2 
antisense ODNs. The 20-bp antisense ODN (TI-AS) 
used for these studies straddles the translation initia- 
tion (TI) site of human BCL2 mRNAs and has been 
shown previously to result in sequence-specific reduc- 
tions in BCL2 protein levels without concomitant alter- 
ations in the levels of other proteins [17]. For studies 
with 3T3 cells, we cultured control-transfected 3T3 cells 
(R596.1) and pSV2-BCL2-transfected cells in medium 
containing 5% fetal calf serum as a source of PDGF and 
other growth factors. Either the antisense (TI-AS) or a 



















FIG. 2. Effects of BCLP antisense oligodeoxynucleotides on 3T3 
cells. The control 3T3 cell line R596.1 (A), the BCL2-antisense-ex- 
pressing cell line R596.3 (B), and the BCL2-expressing cell line 
R596.2 (C) were seeded at low density into cultures containing 5% 
(vol:vol) 68”Ctreated serum. The antisense ODN (TI-AS) (dotted 
bars), sense ODN (TI-S) (striped bars), or diluent (open bars) was 
added to cultures and relative levels of DNA synthesis (kcpm) were 
measured 3 days later, following a 16-h incubation with 5 &i/ml of 
[3H]thymidine. Cell densities, estimated by phase-microscopy, were 
consistent with the measured DNA synthesis in cultures (not shown). 
Data represent the mean i standard deviation of triplicate cultures. 
The percentage inhibition of DNA synthesis in cultures containing 
the TI-AS (100 FM) ODN was calculated relative to control cultures 
that received diluent and is shown in parenthesis for each cell line. 
control sense ODN (TI-S) was then added to cultures, 
and relative levels of DNA synthesis were subsequently 
measured. 
As shown in Fig. 2, the antisense ODN suppressed 
DNA synthesis in cultures of both control and pSV2- 
BCL2-transfected 3T3 cells, whereas the control ODN 
had comparably little effect. Sequence-specific inhibi- 
tion of cellular replication was also confirmed by cell 
counting for cultures treated with the antisense ODN 
(not shown). Importantly, the extent of inhibition of 
DNA synthesis by the BCL2 antisense ODN was less in 
the pSV2-BCL2-transfected cells (R596.2) than in the 
control pSV2-gpt-transfected cells (R596.1) (53% ver- 
sus 73%), as might be expected given the higher levels of 
BCL2 mRNA in the R596.2 cells (Fig. 3). To further test 
the specificity of this antisense ODN-mediated inhibi- 
tion of DNA synthesis in cultures of 3T3 cells, we also 
made use of a cell line (R596.3) we described previously 
[lo] that expresses a human BCL2 cDNA in antisense 
orientation (Fig. 3). The human BCL2 antisense tran- 
scripts produced in these cells have only 66% homology 
with endogenous mouse BCL2 mRNAs [15] and thus 
did not impair serum-induced DNA synthesis (Fig. 2B). 
Addition of the BCLS-sense ODN (TI-S) to cultures of 
these pSV2-BCL2 antisense-expressing R596.3 cells 
failed to inhibit serum-induced DNA synthesis, thus ex- 
cluding the possibility that the mere formation of 
ODN-RNA heteroduplexes in cells inhibited DNA 
growth through nonspecific mechanisms such as induc- 
tion of interferon production (Fig. 2B). The BCL2 anti- 
sense ODN (TI-AS) in contrast, impaired serum-in- 
duced DNA synthesis in these R596.3 cells to about the 
same extent as in cultures of control R596.1 cells (80% 
versus 73%). Moreover, experiments using an addi- 
tional control ODN that had the same nucleotide com- 
position as the TI-AS ODN but with scrambled se- 
quence excluded the possibility that the observed reduc- 
tions in DNA synthesis were attributable to cold 
thymidine inhibition (not shown). It is difficult, how- 
ever, to make additional quantitative comparisons 
among the various 3T3 cell lines used here for antisense 
experiments, because the 20’ mer TI-AS ODN is per- 
fectly complementary with the human BCL2 mRNAs 
derived from the pSV2-BCL2 expression plasmid but 
has two mismatches in its 3’ end with endogenous mouse 
ABC GA,1 
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FIG. 3. RNA blot analysis of BCLB-expressing 3T3 cells. For 
RNA blot analysis, polyadenylated mRNA was purified from control 
pSV2-gpt-transfected 3T3 cells (R596.1) and from cells stably trans- 
fected with pSV2-BCL2 expression constructs that produce either 
sense (R596.2) or antisense (R596.3) human BCL2 mRNAs. These 
pSV2-BCLB-derived transcripts include the expected 1.4-kbp BCLP/ 
CAT fusion mRNA and a 2.4-kbp mRNA resulting because of an 
upstream cryptic transcription initiation site in this vector (see Ref. 
[lo], and unpublished). Approximately 5 Kg of mRNA was subjected 
to RNA blot analysis, using either 32P-labeled hybridization probes 
derived from human (left) or murine (right) BCLZ cDNAs. 
Shown in the left panel is the autoradiogram resulting from a l-day 
exposure of a blot containing RNAs from (A) control 3T3 cells, pSV2- 
gpt; (B) R596.3 cells, pSV2-BCL2-AS; and (C) R596.2 cells, pSV2- 
BCL2. 
The right panel represents the results of a lo-day exposure of a blot 
containing RNA from the control 3T3 cell line R596.1 (A) that were 
either proliferating (lane 1) or quiescent (lane 2) at the time of har- 
vesting RNA. Rehybridization of these blots with a mouse fl2-micro- 
globulin probe confirmed equivalent amounts of mRNA for each sam- 
ple (not shown). 
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BCL2 mRNAs [15, 171. Nevertheless, these experi- 
ments (Fig. 2) provide supportive evidence that BCL2 
contributes to the growth factor-induced cell cycle 
events leading to DNA synthesis in these fibroblast cell 
lines. 
Because suppression by BCL2 antisense ODNs of 
DNA synthesis in cultures of the control 3T3 cell line 
(R596.1) suggested a role for the endogenous mouse 
BCL2 gene in controlling the proliferation of these fibro- 
blasts, we also explored the regulation of BCL2 mRNA 
levels in these cells. As shown in Fig. 3, 3T3 fibroblasts 
contained very low, but detectable levels of the expected 
7.5 and 2.4-kbp mouse BCL2 mRNAs when stimulated 
with serum but not when quiescent. When taken to- 
gether with the antisense experiments, these findings 
imply that serum-derived growth factors can induce ex- 
pression of the BCL2 proto-oncogene in these fibro- 
blasts, and that this event is important for cell cycle 
events leading to DNA synthesis. 
Investigations of inositol phosphates, Cazt and protein 
kinase C. With its mitochondrial location [a], presum- 
ably the p26-BCL2 protein regulates some aspect of mi- 
tochondrial function. Though mitochondria are per- 
haps best known for their role in oxidative-phosphory- 
lation, these organelles may also participate in 
regulation of cytosolic calcium ion concentrations and 
other events that have been implicated in growth fac- 
tor-mediated signal transduction [25,26]. Unloading of 
sequestered Ca2+ from mitochondria, for example, has 
been reported to occur in 3T3 fibroblasts following stim- 
ulation with PDGF [27]; thus raising the possibility that 
these organelles may contribute to the regulation of 
Ca’+-dependent enzymes such as PKC. A recent report 
that BCL2-transfected 3T3 fibroblasts exhibit in- 
creased PI turnover and elevated PA synthesis [7], 
therefore, prompted us to further investigate these sig- 
nalling pathways as potential explanations for the re- 
duced dependence on competence-inducing growth fac- 
tors observed in our BCLB-expressing 3T3 cell lines. PI 
turnover has been associated with production of IP, (an 
intracellular regulator of calcium ion fluxes) through 
the phosphodiesteratic cleavage of phosphatidylinositol 
bisphosphate which yields IP, and 1,2,-diacylglycerol 
(DAG). The latter, DAG, is a critical allosteric regulator 
of PKC activity [8,9]. DAG can also be converted to PA 
through phosphorylation by DAG kinase [28]. Since 
treatment of rodent fibroblasts with PA or its related 
phospholipids has been reported to stimulate mitogene- 
sis and phosphatidylinositol bisphosphate hydrolysis 
[29,30], the elevated levels of PA reported previously in 
BCLB-expressing 3T3 cells [ 71 would be expected to in- 
crease IP, and DAG production and thus result in PKC 
activation. 
For these reasons, we: (1) determined relative rates of 













FIG. 4. Inositol triphosphate production in 3T3 cell lines. 3T3 
cells expressing BCLP, RAS, or pSV2-gpt were labeled in serum 
free, inositol-free DMEM with [3H]myo-inositol (1 &i/ml) quiescent 
cells were then stimulated with Bradykinin (1 PM, 0) or PDGF (20 
rig/ml, I) for 5 min and [3H]inositol trisphosphate levels were deter- 
mined. Results are expressed as means f SEM from four experi- 
ments. 
solic Ca2+ ions; and (3) examined the status of PKC in 
BCL2-expressing 3T3 cells. Fig. 4 shows the results of 
IP, synthesis measurements for BCL2-expressing and 
control-transfected 3T3 cells, before and after stimula- 
tion with growth factors. RAS-transformed cells were 
examined here as a control, since these cells have been 
reported to display markedly increased production of 
IP, in response to bradykinin but reduced synthesis of 
this inositol phosphate when stimulated with PDGF 
[31, 321. As shown in Fig. 2, bradykinin induced similar 
rates of IP, synthesis in BCL2-expressing and negative 
control (GPT) cells. Though PDGF induced slightly 
higher rates of IP, synthesis in BCLB-expressing 3T3 
cells, the results were not statistically significant (Fig. 
4). Furthermore, no basal elevations of IP, levels were 
noted in BCL2-expressing 3T3 cell lines. RAS-trans- 
formed 3T3 cells, in contrast, exhibited the expected 
alterations in their regulation of IP, production follow- 
ing stimulation with bradykinin or PDGF [31, 321. 
Thus, increased IP, production cannot account for the 
diminished growth factor requirements seen in our 
pSV2 BCL2-transfected 3T3 cell lines. Similarly, when 
basal and PDGF-induced elevations in cytosolic Ca2+ 
concentrations were examined in pSV2-BCL2-express- 
ing 3T3 cells, no differences from control cells were 
noted (Fig. 5). 
We next measured relative levels of immunodetect- 
able PKC in the 3T3 cell lines, as an indirect means of 
assessing whether p26 BCL2 overexpression leads to 
activation of these kinases. Tonic stimulation with 
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FIG. 5. Measurements of cytosolic Ca2+ concentrations in BCL2-expressing 3T3 cells. 3T3 cells loaded with 15 pM Fura 2/AM were 
stimulated with 40 rig/ml PDGF, and fluorescence of single representative cells was measured as described previously [19]. At left, mean 
(-+ standard deviation) basal and peak cytosolic Ca2+ measurements are presented for control R596.1 and BCLB-expressing R596.2 cells (n = 4 
for R596.1; n = 7 for R596.2). No significant difference in the delay time (time from PDGF addition until maxima1 cytosolic Ca’+) was noted for 
the two types of cells (mean t = 4.7 f 3.2 s for R596.1; t = 6.4 2 2.6 for R596.2 cells). 
At right are shown representative results for R596.1 (top) and R596.2 (bottom) cells, where cytosolic Ca2+ concentrations were measured 
continuously over a period of 150 s following addition of PDGF. 
DAG-like phorbol esters or by expression of particular 
transforming oncogenes such as RAS that induce DAG 
production has been shown to result in down-regulation 
of PKC [8, 33, 341. As shown in Fig. 6A, immunoblot 











FIG. 6. Effects of BCL2 on PKC Levels and Function. (A) Deter- 
gent lysates were prepared from quiescent R596.1 (GPT) (lane 1); 
R596.2, R658.2 (BCLB) (lanes 2 and 4); and R596.7, C74-81 (RAS) 
(lanes 3 and 5) cell lines. Cell extracts were then normalized for pro- 
tein content and 100 pg was size-fractionated by SDSpolyacrylamide 
gel electrophoresis (7.5% gels) prior to transfer to nitrocellulose 
membranes. Blots were incubated with anti-PKC antibody 201, fol- 
lowed by lZ51-labeled protein A. Loading of equal amounts of protein 
was confirmed by staining of a portion of filters with Ponceau S (not 
shown). The p77 PKC protein bands are shown. Similar results were 
obtained in two other experiments. (B) Quiescent a*PO,-labeled cells 
were either treated (+) or not treated (p) with 100 rig/ml TPA prior 
to lysis, normalization for protein content, and immunoprecipitation 
of p68-MARCKS. Proteins were size-fractionated by SDS-PAGE 
(7.5% gel). Data are representative of three experiments. Cell lines 
analyzed included: (1) R596.1 (GPT); (2) R596.2 (BCLZ); (3) R658.2 
(BCLB). 
(R596.2; R658.2) demonstrated levels of p77-PKC com- 
parable to negative control-transfected cells (R596.1). 
RAS-transformed cells, in contrast, contained only 
about half as much total PKC, consistent with constitu- 
tive stimulation of these enzymes in cells that express a 
RAS oncogene [33, 341. 
In uivo PKC activity was also assessed in BCL2-ex- 
pressing 3T3 cell lines by examination of relative levels 
of phosphorylation of a major PKC substrate, p68 
MARCKS [al, 221. As shown in Fig. 6B, basal incorpora- 
tion of 32P0, into immunoprecipitable p68 MARCKS 
was not elevated in quiescent BCL2-expressing cell 
lines relative to control transfected (GPT) cell lines. 
Moreover, a similar fold increased in 32P0,-incorpora- 
tion into p68 MARCKS was induced by the phorbol es- 
ter tetradecanoylphorbol acetate (TPA) in these cells, 
suggesting that PKC responses are not blunted in 
BCL2-expressing 3T3 cells, as has been reported for 
some oncogene-transformed 3T3 cells [34]. When taken 
together with the measurements of PKC levels in 
BCL2-expressing 3T3 cells, these findings (Fig. 6) argue 
against a role for PKC activation in the BCLB-mediated 
partial abrogation of PDGF and EGF requirements for 
3T3 fibroblast proliferation. 
Conclusions. In summary, the data presented here 
demonstrate that overexpression of the mitochondrial 
protein p26 BCLZ in NIH3T3 fibroblasts markedly re- 
duces concentrations of competence-inducing growth 
factors necessary for achieving maximal levels of DNA 
synthesis. Previous investigations of the regulation of 
BCL2 gene expression have demonstrated a correlation 
between cellular proliferation and levels of BCL2 
mRNAs, suggesting that this proto-oncogene may par- 
ticipate in the control of normal cellular growth [6,35]. 
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Our findings in BCL2-transfected 3T3 fibroblasts pro- 
vide further strong support that BCL2 enhances cellu- 
lar growth, in addition to its effects on cellular survival. 
Moreover, since p26 BCL2 is found exclusively in mito- 
chondria [ 21, our data imply that specific unknown alter- 
ations in mitochondrial function can partially supplant 
the need for competence-inducing growth factors in 
stimulating cellular proliferation. 
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